Related Articles
Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway
Experimental chondrocyte hypertrophy is promoted by the activation of discoidin domain receptor 2
Downregulation of discoidin domain receptor 2 in A375 human melanoma cells reduces its experimental liver metastasis ability
AKT1 and AKT2 mutations in lung cancer in a Japanese population